NET PROFIT (x1000 EUR)
EMPLOYEES
Glucox Biotech AB
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
-153
|
-127
|
-121 |
| EBITDA |
-66
|
-62
|
-72 |
| Total assets |
612
|
268
|
283 |
| Current assets |
36
|
19
|
74 |
| Current liabilities |
22
|
24
|
6 |
| Equity capital |
-156
|
-3
|
135 |
| - share capital |
140
|
140
|
152 |
| Employees (average) |
1
|
1
|
1 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
-25.5%
|
-1.1%
|
47.7% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-25.0%
|
-47.4%
|
-42.8% |
| Current ratio |
163.6%
|
79.2%
|
1233.3% |
| Return on equity (ROE) |
98.1%
|
4233.3%
|
-89.6% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.